Author:
Zhu Shengjun,Dou Mingjin,Huang Guihua
Publisher
Springer Science and Business Media LLC
Subject
Drug Discovery,Pharmaceutical Science,Agronomy and Crop Science,Ecology,Aquatic Science,General Medicine,Ecology, Evolution, Behavior and Systematics
Reference20 articles.
1. Hanioka N, Ozawa S, Jinno H, Tanaka-Kagawa T, Nishimura T, Ando M, et al. Interaction of irinotecan (CPT-11) and its active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38) with human cytochrome P450 enzymes[J]. Drug Metab Dispos Biol Fate Chem. 2002;30(4):391–6.
2. Wang X, Rao Z, Qin H, Zhang G, Ma Y, Jin Y, et al. Effect of hesperidins on the pharmacokinetics of CPT-11 and its active metabolite SN-38 by regulating hepatic Mrp2 in rats. Biopharm Drug Dispos. 2016;37(7):421–32.
3. Lavelle F, Bissery MC, André S, et al. Preclinical evaluation of CPT-11 and its active metabolite SN-38. Semin Oncol. 1996;23(3):11–20.
4. Pommier Y. Topoisomerase I inhibitors: camptothecins and beyond. [J]. Nat Rev Cancer. 2006;6(10):789.
5. Husain I, Mohler JL, Seigler HF, Besterman JM. Elevation of topoisomerase I messenger RNA, protein, and catalytic activity in human tumors: demonstration of tumor-type specificity and implications for cancer chemotherapy. Cancer Res. 1994;54(2):539–46.
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献